AbbVie Lifts 2026 Earnings Outlook Despite Q1 Profit Decline

AbbVie, Inc. (ABBV) has increased its adjusted earnings per share (EPS) projections for fiscal year 2026, signaling confidence in its operational trajectory despite a mixed start to the current year. The guidance hike suggests the company is successfully navigating its product pipeline and market expansion. For the first quarter, the company reported a significant top-line increase, with revenue rising 12.5% to $15.01 billion, compared to $13.34 billion in the prior-year period. On an operational basis, net revenues saw a growth of 10.3%, demonstrating robust demand for its pharmaceutical portfolio. However, the bottom line faced pressure, with net profit falling to $695 million, or $0.39 per share, down from $1.28 billion, or $0.72 per share, a year ago. Adjusted earnings for the quarter remained stronger at $4.71 billion, representing $2.65 per share. Looking toward the full year, AbbVie now expects adjusted EPS to range between $14.08 and $14.28, an improvement over the previous estimate of $13.96 to $14.16. This updated outlook incorporates a $0.41 per share unfavorable impact stemming from acquired in-process research and development (IPR&D) and milestone expenses. Market participants responded favorably to the revised guidance, with shares climbing approximately 2.3% to $202.00 in pre-market activity. The move indicates that investors are prioritizing the company's long-term earnings potential over short-term net profit fluctuations.